M.

Shiro Yokohama, Masashi Yoneda, Masakazu Haneda, Satoshi Okamoto, Mituyoshi Okada, Kazunobu Aso, Takenao Hasegawa, Yoshihiko Tokusashi, Naoyuki Miyokawa, Kimihide Nakamura – 20 September 2004 – The therapeutic efficacy of angiotensin II receptor antagonist, losartan, was studied in patients with nonalcoholic steatohepatitis (NASH). Seven patients with both NASH and hypertension were treated with losartan (50 mg/d) for 48 weeks.

Ke Qi, Hongming Qiu, Dongfeng Sun, Gerald Y. Minuk, Michael Lizardo, John Rutherford, F. William Orr – 20 September 2004 – Metastases rarely occur in human livers with cirrhosis in clinical studies. We postulated that this phenomenon would also occur in experimental cirrhosis. Cirrhosis was established in C57BL/6 mice by carbon tetrachloride (CCl4) gastrogavage. B16F1 melanoma cells were injected into the mesenteric vein to induce hepatic metastases. Contrary to our postulate, there was greater than 4‐fold increase in metastasis in animals with cirrhosis compared to controls.

Carla S. Coffin, Tram N.Q. Pham, Patricia M. Mulrooney, Norma D. Churchill, Tomasz I. Michalak – 20 September 2004 – Antibodies against virus nucleocapsid (anticore) normally accompany hepadnaviral hepatitis but they may also occur in the absence of symptoms and other serological indicators of the infection. This situation can be encountered following a clinically and serologically unapparent exposure to hepatitis B virus (HBV) or after recovery from hepatitis B.

William J. Wall – 16 September 2004

Antonio Rafecas, Gabriel Rufí, Juan Figueras, Juan Fabregat, Xavier Xiol, Emilio Ramos, Jaime Torras, Laura Lladó, Teresa Serrano – 16 September 2004 – Until recently, human immunodeficiency virus (HIV) infection was considered an absolute contraindication for liver transplantation in Spain. We present the first 4 cases of liver transplantation (LT) carried out in our center in patients infected with HIV and coinfected by the hepatitis C virus (HCV), immunosuppressed with cyclosporine A (CyA) and basiliximab, but without steroids.

Roberto J. Firpi, Manal F. Abdelmalek, Consuelo Soldevila‐Pico, Roniel Cabrera, Jonathan J. Shuster, Douglas Theriaque, Alan I. Reed, Alan W. Hemming, Chen Liu, James M. Crawford, David R. Nelson – 16 September 2004 – Determinants of progression to cirrhosis in hepatitis C virus (HCV) infection have been well described in the immunocompetent population but remain poorly defined in liver transplant (LT) recipients. This cohort study determines the factors contributing to the development of fibrosis and its rate of progression in the allograft.

Suzanne Norris, Chris Taylor, Paolo Muiesan, Bernard C. Portmann, Alex S. Knisely, Matthew Bowles, Mohamed Rela, Nigel Heaton, John G. O'Grady – 16 September 2004 – Liver transplantation (LT) in human immunodeficiency virus (HIV)‐positive individuals is considered to be an experimental therapy with limited reported worldwide experience, and little long‐term survival data. Published data suggest that the short‐term outcome is encouraging in selected patients.

Mitchell L. Shiffman, R. Todd Stravitz, Melissa J. Contos, A. Scott Mills, Richard K. Sterling, Velimir A. Luketic, Arun J. Sanyal, Adrian Cotterell, Daniel Maluf, Marc P. Posner, Robert A. Fisher – 16 September 2004 – Hepatitis C virus (HCV) recurs in nearly all patients after liver transplantation. This recurrence is associated with progressive fibrosis and graft loss. It remains unclear whether the natural course of HCV recurrence is altered in patients who undergo living donor liver transplantation (LDLT).

Robert S. Brown – 16 September 2004